Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07047209 · ClinicalTrials.gov registry record · Phase 2

Trial of Oral Digoxin in Individuals With Amyotrophic Lateral Sclerosis (ALS)

A Phase 2 study of ALS (Amyotrophic Lateral Sclerosis), sponsored by Massachusetts General Hospital.

Active
Registry status
Phase 2
Development phase
40
Enrollment target
3
Study locations

NCT07047209: Active Phase 2 study of ALS (Amyotrophic Lateral Sclerosis), sponsored by Massachusetts General Hospital.

NCT07047209 is a Phase 2 study of ALS (Amyotrophic Lateral Sclerosis) that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 40 participants, below the 361-participant average among 6 other ALS (Amyotrophic Lateral Sclerosis) trials with a reported enrollment target (89% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07047209, a Phase 2 study of ALS (Amyotrophic Lateral Sclerosis), is active but no longer recruiting, sponsored by Massachusetts General Hospital.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target
3
Study locations

Study Summary

This clinical trial is being conducted to learn about safety and tolerability of digoxin in ALS individuals. Additionally, this trial aims to better understand if digoxin has an effect on slowing neurodegeneration in ALS.

Conditions Studied

ALS (Amyotrophic Lateral Sclerosis)

Interventions

  • DRUG Digoxin

Study Locations (3)

Florida

  • Nova Southeastern University - Davie

Illinois

  • Northwestern Universsity - Chicago

Massachusetts

  • MGH - Boston

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-05-27
Est. Completion 2026-04
Phase Phase 2

Sponsor

Massachusetts General Hospital

2,032 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07047209

The ClinicalTrials.gov registry entry for NCT07047209 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 361-participant average among 6 other ALS (Amyotrophic Lateral Sclerosis) trials with a reported enrollment target (89% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with ALS (Amyotrophic Lateral Sclerosis) appearing as the primary indexed condition, and to 1 intervention - of which Digoxin is the first listed.

NCT07047209 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, Illinois, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT07047209 about?

NCT07047209 is a clinical study titled "Trial of Oral Digoxin in Individuals With Amyotrophic Lateral Sclerosis (ALS)". This clinical trial is being conducted to learn about safety and tolerability of digoxin in ALS individuals. Additionally, this trial aims to better understand if digoxin has an effect on slowing neurodegeneration in ALS.

What is the current status of trial NCT07047209?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-05-27. Estimated completion is 2026-04.

What conditions does trial NCT07047209 study?

This clinical trial studies the following conditions: ALS (Amyotrophic Lateral Sclerosis).

What interventions are being tested in trial NCT07047209?

The interventions under investigation include: Digoxin (DRUG).

Who is sponsoring clinical trial NCT07047209?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07047209 being conducted?

This trial has 3 study locations across Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for ALS (Amyotrophic Lateral Sclerosis)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

ALS (Amyotrophic Lateral Sclerosis)

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.